The hippo signaling pathway in pancreatic cancer
(2019) In Anticancer research 39(7). p.3317-3321- Abstract
Hippo signaling is a key regulator of organ size, tissue hemostasis and regeneration. Dysregulation of the Hippo pathway has been recognized in a variety of human cancers, including pancreatic cancer. YES-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are the two major downstream effectors of the Hippo pathway. YAP and TAZ have been found to promote pancreatic tumor development and progression, even in the absence of mutant Kirsten RAS (KRAS). Pancreatic cancer is associated with an abundant stromal reaction leading to tumor growth and immune escape. It has been found that YAP and TAZ modulate behavior of pancreatic stellate cells and recruitment of tumor-associated macrophages and myeloid-derived... (More)
Hippo signaling is a key regulator of organ size, tissue hemostasis and regeneration. Dysregulation of the Hippo pathway has been recognized in a variety of human cancers, including pancreatic cancer. YES-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are the two major downstream effectors of the Hippo pathway. YAP and TAZ have been found to promote pancreatic tumor development and progression, even in the absence of mutant Kirsten RAS (KRAS). Pancreatic cancer is associated with an abundant stromal reaction leading to tumor growth and immune escape. It has been found that YAP and TAZ modulate behavior of pancreatic stellate cells and recruitment of tumor-associated macrophages and myeloid-derived suppressor cells. Moreover, YAP and TAZ are associated with chemoresistance and poor prognosis in pancreatic cancer. This review dissects the role of Hippo signaling in pancreatic cancer, focusing on molecular mechanisms and prospects for future intervention.
(Less)
- author
- Ansari, Daniel LU ; Ohlsson, Henrik LU ; Althini, Carl ; Bauden, Monika LU ; Zhou, Qimin LU ; Hu, Dingyuan LU and Andersson, Roland LU
- organization
- publishing date
- 2019-07
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Chemoresistance, EMT, Hippo pathway, Immunomodulation, Pancreatic Cancer, Review, Stroma, TAZ, Treatment, Tumor progression, YAP
- in
- Anticancer research
- volume
- 39
- issue
- 7
- pages
- 5 pages
- publisher
- International Institute of Cancer Research
- external identifiers
-
- pmid:31262852
- scopus:85068253186
- ISSN
- 0250-7005
- DOI
- 10.21873/anticanres.13474
- language
- English
- LU publication?
- yes
- id
- 00bf0b24-b9fe-4e3f-9e6b-5a56b6e86fca
- date added to LUP
- 2019-07-11 09:49:02
- date last changed
- 2024-08-08 03:00:15
@article{00bf0b24-b9fe-4e3f-9e6b-5a56b6e86fca, abstract = {{<p>Hippo signaling is a key regulator of organ size, tissue hemostasis and regeneration. Dysregulation of the Hippo pathway has been recognized in a variety of human cancers, including pancreatic cancer. YES-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are the two major downstream effectors of the Hippo pathway. YAP and TAZ have been found to promote pancreatic tumor development and progression, even in the absence of mutant Kirsten RAS (KRAS). Pancreatic cancer is associated with an abundant stromal reaction leading to tumor growth and immune escape. It has been found that YAP and TAZ modulate behavior of pancreatic stellate cells and recruitment of tumor-associated macrophages and myeloid-derived suppressor cells. Moreover, YAP and TAZ are associated with chemoresistance and poor prognosis in pancreatic cancer. This review dissects the role of Hippo signaling in pancreatic cancer, focusing on molecular mechanisms and prospects for future intervention.</p>}}, author = {{Ansari, Daniel and Ohlsson, Henrik and Althini, Carl and Bauden, Monika and Zhou, Qimin and Hu, Dingyuan and Andersson, Roland}}, issn = {{0250-7005}}, keywords = {{Chemoresistance; EMT; Hippo pathway; Immunomodulation; Pancreatic Cancer; Review; Stroma; TAZ; Treatment; Tumor progression; YAP}}, language = {{eng}}, number = {{7}}, pages = {{3317--3321}}, publisher = {{International Institute of Cancer Research}}, series = {{Anticancer research}}, title = {{The hippo signaling pathway in pancreatic cancer}}, url = {{http://dx.doi.org/10.21873/anticanres.13474}}, doi = {{10.21873/anticanres.13474}}, volume = {{39}}, year = {{2019}}, }